Alzheimer's disease histologically proven studied by MRI and MRS: Two cases

Longo, Renata; Giorgini, Adelma; Magnaldi, S; Pascazio, Lorenzo; Ricci, Claudio

doi:10.1016/0730-725x(93)90249-d

Cited by 16 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients of Shetty and Huang [38] are the same as those of Huang et al [39], and the subjects in Miller et al [40] and Moats et al [41] were a subset of the later larger study by Shonk et al [42]. Tedeschi et al [43] performed multiple comparisons between different regions of the brain in their spectroscopic images, but unfortunately, reported only data for the areas which were significantly different between AD and control; Longo et al [44] and Kario et al [8] had insufficient patients with dementia (n = 2). The number by each data point refers to the study number in table 1.…”

Section: Ad and Other Dementiasmentioning

confidence: 99%

A Comprehensive Review of Proton Magnetic Resonance Spectroscopy Studies in Dementia and Parkinson’s Disease

Firbank¹,

Harrison²,

O’Brien³

2002

Dement Geriatr Cogn Disord

124

View full text Add to dashboard Cite

We reviewed the literature of proton magnetic resonance spectroscopy (MRS) in dementia and Parkinson’s disease (PD) and quantitatively compared the reported values of the markers N-acetyl aspartate (NAA), choline, and myo-Inositol between control and disease groups. We analysed a total of 27 reports in dementia. Combining the quantitative data from these showed a relative decrease of 15% in NAA level in the temporal lobe tissue in patients with Alzheimer’s disease (AD) compared with controls. The rest of the brain showed a seemingly uniform 10% decrease in NAA levels in AD compared with controls. myo-Inositol was raised by about 15%, again uniformly throughout the brain, but there was no evidence for changed levels of choline. We found 15 reports of MRS in PD, which show a small decrease (5%) in the NAA level in the lentiform nucleus compared with controls. In progressive supranuclear palsy (PSP), there is a greater decrease in NAA levels in the frontal region and the lentiform nucleus. This may aid in the diagnosis of PSP. Further research is needed to determine spectroscopic changes in other dementias, to monitor how markers change with disease progression and to establish clinical utility.

show abstract

Section: Ad and Other Dementiasmentioning

confidence: 99%

A Comprehensive Review of Proton Magnetic Resonance Spectroscopy Studies in Dementia and Parkinson’s Disease

Firbank¹,

Harrison²,

O’Brien³

2002

Dement Geriatr Cogn Disord

124

View full text Add to dashboard Cite

show abstract

“…43 While fMRI detects regional changes in deoxyhemoglobin concentration reflecting focal brain activity in response to a variety of stimuli and memory tasks, 44 MR Perfusion has been shown to have about 85-95% sensitivity for patients with mild or moderate AD with a range of 88-95% specificity. 45;46 Estimation of regional metabolite levels of N-acetylaspartate (NAA), glutamine and glutamate, c-aminobutyric acid, myo-inositol, glycine, choline, creatine and phosphocreatine, lipids, and lactate in brain tissue of AD patients can be obtained non-invasively through proton MRS. 47 Some MRS studies have shown regional decreases in NAA in patients with AD in temporal and parietal cortices, [48][49][50][51] while also demonstrating a positive correlation between the degree of NAA reductions and disease severity by neuropathologic criteria. 52;53 MRS has also been applied to monitor response to therapeutic interventions in AD.…”

Section: Functional Neuroimagingmentioning

confidence: 97%

Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease

Villemagne

Rowe

Macfarlane

et al. 2005

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

“…Estimation of regional metabolite levels of N-acetylaspartate (NAA), glutamine and glutamate, γ-aminobutyric acid, myo-inositol, glycine, choline, creatine and phosphocreatine, lipids, and lactate in brain tissue of AD patients can be obtained noninvasively through proton MRS 222 . Some MRS studies have shown regional decreases in NAA in patients with AD in temporal and pa- rietal cortices [223][224][225][226] while also demonstrating a positive correlation between the degree of NAA reductions and disease severity by neuropathologic criteria 227,228 . MRS has also been applied to monitor response to therapeutic interventions in AD 229,230 .…”

Section: Functional Neuroimagingmentioning

confidence: 98%

La Lunga Attesa: Towards a Molecular Approach to Neuroimaging and Therapeutics in Alzheimer's Disease

Villemagne

Cappai

et al. 2006

Neuroradiol J

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by the gradual onset of dementia. The pathological hallmarks of the disease are Aβ amyloid plaques, neurofibrillary tangles (NFT), synaptic loss and reactive gliosis. Current diagnosis of AD is made by clinical, neuropsychologic, and neuroimaging assessments. Routine structural neuroimaging evaluation with computed tomography (CT) and magnetic resonance imaging (MRI) is based on nonspecific features such as atrophy, a late feature in the progression of the disease, hence the crucial importance of developing new approaches for early and specific recognition at the prodromal stages of AD. Functional neuroimaging techniques such as functional magnetic resonance imaging (fMRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET) and single photon emission computed tomography (SPECT), possibly in conjuction with other related Aβ biomarkers in plasma and CSF, could prove to be valuable in the differential diagnosis of AD, as well as in assessing prognosis. With the advent of new therapeutic strategies aimed at reducing the Aβ amyloid burden in the brain, there is increasing interest in the development of MRI contrast agents and PET and SPECT radioligands that will permit the assessment of Aβ amyloid burden in vivo.

show abstract

Alzheimer's disease histologically proven studied by MRI and MRS: Two cases

Cited by 16 publications

References 15 publications

A Comprehensive Review of Proton Magnetic Resonance Spectroscopy Studies in Dementia and Parkinson’s Disease

A Comprehensive Review of Proton Magnetic Resonance Spectroscopy Studies in Dementia and Parkinson’s Disease

Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease

La Lunga Attesa: Towards a Molecular Approach to Neuroimaging and Therapeutics in Alzheimer's Disease

Contact Info

Product

Resources

About